An open-label, randomized, single-dose, two-treatment, single period, parallel- group bioequivalence study of Fingolimod 0.5 mg capsules manufactured by MSN Laboratories Limited, India (Test) with GILENYAâ?¢ capsules containing fingolimod 0.5 mg manufactured by Novartis Pharmaceuticals Corporation, U.S.A. (Reference), in healthy, adult, male, human subjects under fasting condition.

MSN Laboratories Ltd0 个研究点目标入组 32 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 32

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Ba/be

入排标准

入选标准

•(i)Healthy, Indian, male, human volunteer aged from 18 to 45 years.
•(ii)Body Mass Index (BMI) should be within 18.0-25.0 kg/m2.
•(iii)Voluntarily willing and capable to give written and signed informed consent prior to participation in the study, according to the form attached in appendix 1.
•(iv)Availability for the entire study period and willingness to adhere to protocol and study requirements.
•(v)Volunteers willing to undergo pre and post-study physical examinations and laboratory investigations.
•(vi)Having no significant disease or abnormal laboratory values on laboratory examination with no clinical relevance, medical history or physical examination during screening.
•(vii)12-lead ECG in resting position and vital signs are within normal limits or showing or abnormalities, which the investigator does not consider of clinical relevance.
•(viii)Normal chest X-Ray findings or findings that have no clinical correlation.
•(ix)Non-smokers [Non-smokers at least 6 months from the day of screening].
•(x)Having not consumed alcohol at least 48 hours prior to the study justified by negative breath-alcohol test and who agree not to consume any amount of alcohol throughout the conduct of the study.
•(xi)Negative urine test for drug of abuse (Amphetamine, barbiturate, tetrahydrocanabinoids, morphine, cocaine and benzodiazepine).

排除标准

•(i)History of allergy or sensitivity to fingolimod or history of any drug hypersensitivity or intolerance, which, in the opinion of the investigator, would compromise the safety of the volunteer if included in the study.
•(ii)History of diseases of liver or hepatic impairment within last one (1) year.
•(iii)Elevated serum transaminases (SGOT/ SGPT) or alkaline phosphatase. (at least 1.5 times of upper normal range).
•(iv)History of mania or hypomania
•(v)Serious, uncontrolled disease (including serious psychological disorders) likely to interfere with the study and/or likely to cause death within the study duration.
•(vi)Participation in another clinical study or a blood donation program or have had blood loss of more than 350 ml.
•(vii)Renal failure (Serum creatinine more than twofold of the > 3 mg/dL).
•(viii)Positive blood test for HIV, HbsAg, HCV or VDRL.
•(ix)Any clinically relevant abnormality (to be determined by the investigator) following review of screening laboratory data and full physical examination.
•(x)Vital sign abnormalities (systolic blood pressure in supine position lower than 100 or higher than 140 mm Hg or diastolic blood pressure lower than 60 or higher than 100 mm Hg or heart rate less than 55 bpm or more than 120 bpm) at screening and at pre-admission physical examination.
•(xi)Evidence of second degree or higher AV block, sick sinus syndrome, prolonged QT interval, ischemic cardiac disease, or congestive heart failure in the 12-lead ECG is resting supine position.
•(xii)Having suffered any illness within a week of starting the study or who have been hospitalized within the last 3 months preceding the start of the study.
•(xiii)Having taken over the counter (OTC) or prescribed medications, including any antihypertensive drugs, enzyme-modifying drugs or any systemic medication within the 07 days prior to the study (However, paracetamol may be permitted up to 03 days prior to the start of the study).
•(xiv)Have a history of substance abuse within the last 5 years.
•(xv)Consumption of xanthine-containing derivatives (coffee, tea, cola drinks, chocolate) within 48 hrs before IMP administration and grapefruit or orange juice for at least 48 hrs prior to IMP administration.
•(xvi)Habit of chewing or inhaling nicotine-containing products (e.g. tobacco) currently or within last six months prior to the study.
•(xvii)Abnormal INR combined with clinical manifestation

研究者

发起方

MSN Laboratories Ltd

相似试验

尚未招募

1 期

A clinical trial to study bioequivalence between 2 formulations of drug called Aliskiren in healthy subjects

CTRI/2010/091/002815ovartis Healthcare Pvt. Ltd.Raheja IT Park, Mind Space - Bld # 6, Hitech City,Village - Madhapur,Hyderabad 500081, India150

已完成

1 期

A single-dose, single period of comparing Formulated Curcumin based drink with Unformulated Curcumin based drink manufactured by Sipwise Beverage Pvt Ltd, in healthy, subjects under fed conditions.

CTRI/2020/09/027701Dr Srividhya Sundararaman8

已完成

1 期

Bioequivalence study of gliclazide 60 mg modified release tablets under fasting conditions

CTRI/2021/01/030614Centaur Pharmaceuticals Pvt Ltd76

已完成

1 期

Bioequivalence study of Pramipexole Prolonged Release Tablets 1.05 mg

CTRI/2020/03/024192Aristo Pharma GmbH46

已完成

不适用

Study to investigate the effect of atorvastatin on the pharmacokinetic properties of telmisartan/s-amlodipine after oral administration in healthy volunteersDiseases of the circulatory system

KCT0000811Chong Kun Dang24